Table 3.
Events | N |
---|---|
After 30 days of follow‐up | |
Primary end point | 31 |
Aortic‐related deaths | 3 |
Worsening | 21 |
AD | 7 |
Secondary end point | 7 |
All‐cause mortality | 4 |
Aortic‐related deaths | 3 |
Non‐aortic‐related deaths | 1 |
Cerebral stroke | 2 |
Hemorrhagic stroke | 1 |
Ischemic stroke | 1 |
Arrhythmia | 1 |
All bleeding | 2 |
BARC 2–5 | 2 |
BARC 3–5 | 2 |
Long‐term follow‐up | |
Long‐term aortic‐related adverse events | 34 |
Aortic‐related deaths | 5 |
Worsening | 21 |
AD | 8 |
Total adverse clinical events | 13 |
All‐cause mortality | 9 |
Aortic‐related deaths | 5 |
Non‐aortic‐related deaths | 4 |
Cerebral stroke | 2 |
Hemorrhagic stroke | 1 |
Ischemic stroke | 1 |
Arrhythmia | 1 |
All bleeding | 5 |
BARC 2–5 | 4 |
BARC 3–5 | 4 |
AD indicates aortic dissection; and BARC, Bleeding Academic Research Consortium.
BARC, bleeding is graded on a scale of 1 to 5, ranging from minor bleeding that is not actionable (type 1) to fatal bleeding (type 5).